Supernus Pharmaceuticals
SUPN
214 hedge funds and large institutions have $951M invested in Supernus Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 91 increasing their positions, 69 reducing their positions, and 26 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
39% more capital invested
Capital invested by funds: $685M → $951M (+$266M)
32% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 69
28% more call options, than puts
Call options by funds: $4.27M | Put options by funds: $3.34M
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
0% more funds holding
Funds holding: 213 → 214 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$24M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$13.5M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$8.36M |
| 4 |
Bank of New York Mellon
New York
|
+$7.52M |
| 5 |
Millennium Management
New York
|
+$7.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.1M |
| 2 |
MRM
Michael R. Murphy
|
-$8.26M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$4.95M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$4.91M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$4.36M |
SUPN Hedge Fund Activity: Q2 2016 in Review
214 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2016, worth a combined $951M — up 39% from $685M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SUPN positions and 26 closed out — a net gain of 3 holders — while 91 added to existing stakes and 69 trimmed.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $24M. The largest seller was Point72 Asset Management, cutting an estimated $16.1M.
- 214 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2016, up from 213 in Q1 2016.
- Funds reported $951M of Supernus Pharmaceuticals stock for Q2 2016, up 39% quarter-over-quarter.
- 29 funds opened new Supernus Pharmaceuticals positions in Q2 2016 and 26 closed out, a net change of +3 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2016 was Fiera Capital (Canada), an estimated $24M added.
- The largest Supernus Pharmaceuticals seller in Q2 2016 was Point72 Asset Management, an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2016.